Article 1
Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage. Sperry JL, Guyette FX, Cotton BA, Luther JF, Utarnachitt RB, Kutcher ME, Daley BJ, Peetz AB, Patel MB, Goodman MD, Claridge JA, Patel N, Harbrecht BG, Hashmi ZG, Zarychanski R, Neal MD, Yazer MH, Martin-Gill C, Vincent LE, Harner AM, Meyer DE, Latimer AJ, Robinson BR, McKnight CL, Hinckley WR, Miller KR, Jansen JO, Martin D, Fox EE, Rosario-Rivera BL, Wisniewski SR; TOWAR Study Group. N Engl J Med. 2026 June 18;394(23):2317-2328.
While prior studies have demonstrated benefits of whole blood compared with component therapy during early in-hospital resuscitation, its role in the prehospital setting remains unclear. In the Type O Whole Blood and Assessment of Age during Prehospital Resuscitation (TOWAR) trial, Sperry and colleagues performed a multicenter randomized trial comparing prehospital low-titer type O whole blood with component therapy in trauma patients with suspected hemorrhagic shock. More than 1,000 patients transported by air medical services to participating trauma centers were enrolled. The primary outcome was 30-day mortality, with secondary outcomes including early mortality, blood product utilization within 24 hours, and in-hospital complications. Although whole blood has been proposed to provide more physiologic resuscitation, improved hemostatic potential, and simplified transfusion logistics, the investigators found no significant differences in mortality or secondary outcomes between groups. Based on these findings, the authors concluded that prehospital whole blood did not provide a meaningful advantage over component therapy.
For trauma surgeons, this study calls into question the assumption that whole blood is uniformly superior to component therapy. Whole blood has gained increasing popularity because it offers a balanced transfusion product and may simplify logistics in the field; however, this large randomized trial failed to demonstrate a survival benefit. It is also worth noting that the 30-day mortality rate in both TOWAR and the recently published SWiFT trial was approximately 26%, substantially lower than that reported in the landmark studies that established balanced transfusion ratios as the standard of care. This likely reflects continued improvements in trauma systems, resuscitation strategies, and hemorrhage control. Importantly, these findings do not suggest that whole blood is harmful or should be abandoned. Rather, they indicate that trauma systems with established whole-blood programs can continue to use them, while centers utilizing component therapy should not feel compelled to make major changes based on current evidence. Taken together, recent randomized trials suggest that rapid hemorrhage control and timely blood product administration may be more important than whether those products are delivered as whole blood or as separate components.
Article 2
Prehospital Whole Blood in Traumatic Hemorrhage — a Randomized Controlled Trial. Smith JE, Cardigan R, Sanderson E, et al.; SWiFT Trial Group. N Engl J Med. 2026 Jun 18;394(23):2305-2316.
While prehospital blood transfusion has been associated with improved survival in patients with traumatic hemorrhagic shock, the optimal composition of blood products in the prehospital setting remains uncertain. In the SWiFT trial, Smith and colleagues conducted a pragmatic, multicenter, phase 3 randomized superiority trial across 10 air ambulance systems comparing leukocyte-depleted low-titer group O whole blood (up to 2 units) with standard component therapy (red blood cells and plasma) in patients with major traumatic hemorrhage requiring prehospital transfusion. Of 942 randomized patients, 641 formed the modified intention-to-treat population after prespecified exclusions (nontraumatic hemorrhage and traumatic cardiac arrest), with primary outcome data available for 616 patients. The primary endpoint—a composite of all-cause mortality or massive transfusion within 24 hours—occurred in 48.7% of patients in the whole blood group and 47.7% in the standard care group (RR 1.02; 95% CI 0.80–1.31; p=0.84). Secondary outcomes, including mortality at 6 hours, 24 hours, 30 days, and 90 days, as well as blood product utilization within 24 hours, organ support, length of stay, and in-hospital complications, were similar between groups. An exception was a higher proportion of patients with prothrombin times above the normal range in the whole blood group (40.7% vs 30.5%; RR 1.31; 95% CI 1.10–1.56), without corresponding differences in clinical bleeding. The authors concluded that prehospital transfusion of up to 2 units of whole blood was not superior to standard of care in reducing the risk of death or massive transfusion within 24 hours.
From a trauma systems perspective, this trial provides high-quality evidence that prehospital administration of up to 2 units of whole blood does not confer superiority over component-based transfusion in reducing early mortality or transfusion requirements in a civilian air ambulance system. Importantly, the absence of a clinical difference persists across survival, transfusion burden, and thrombotic safety endpoints, suggesting that the theoretical advantages of whole blood (logistic simplicity and balanced composition), may not translate into measurable outcome improvement at this dose and within this deployment model. The isolated alteration in coagulation parameters likely reflects storage-related degradation of plasma factors rather than a clinically meaningful signal. Taken together, these findings support continued equipoise between whole blood and component therapy in prehospital trauma resuscitation. System design decisions should therefore remain driven by logistics, blood supply infrastructure, and operational feasibility rather than expectations of superiority in early survival outcomes. Further work is needed to define whether higher-volume transfusion strategies or specific phenotypes of hemorrhagic shock may derive differential benefit from whole-blood–based resuscitation strategies.
